Quantcast

Latest advanced prostate cancer Stories

2014-05-16 08:25:48

LINCOLNSHIRE, Ill., May 16, 2014 /PRNewswire/ -- TOLMAR Pharmaceuticals, Inc., focused on specialty pharmaceutical products, today announced that, effective May 8, 2014, the company holds exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in the U.S. and Puerto Rico. ELIGARD is a prescription medication for the palliative treatment (management of symptoms) of advanced prostate cancer. http://photos.prnewswire.com/prnvar/20140515/88265...

2014-03-05 11:06:28

Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods. Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer. The research showed depletion of the compound cholesteryl ester significantly reduced prostate cancer cell...

2013-12-09 23:21:19

Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA (PRWEB) December 09, 2013 Men suffering from highly advanced prostate cancer have new hope for longer survival times based on a recent clinical trial, the interim results of which were just announced by the National Institutes of Health. The findings suggest that physicians can immediately consider changing their clinical practice...

2013-04-12 15:53:17

Mount Sinai researchers present targets, treatments for prostate, colon, and ovarian cancer at the American Association for Cancer Research Annual Meeting Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting. The meeting took place April 6-10, 2013 in Washington, DC. Natural Product From Soy May Be Effective in...

2012-02-01 10:22:54

Drug compound designed and developed in academic research lab A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer. Based on the strength of the data from the phase III trial, it is anticipated that the biopharmaceutical company Medivation, which licensed MDV3100, will file a new drug application with...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related